Arqule, Inc.

Daiichi Sankyo Company, Limited

Daiichi Pharmaceutical Co., Ltd.

Opna Immuno-oncology Sa

Hiroaki Inagaki

Kiyoshi Nakayama

Jean-Marc Lapierre

Yusuke Ota

Sudharshan Eathiraj

Takayuki Momose

Tomoyuki Tsunemi

Makoto Takemura

Hisashi Takahashi

Brian Schwartz

Rie Miyauchi

Nivedita Namdev

Satoshi Komoriya

Yoshihiro Shibata

Takashi Odagiri

Toshifumi Tsuda

Ying Zhang

Kenichi Yoshida

Wayne Spevak

Jiazhong Zhang

Chao Zhang

Guoxian Wu

Songyuan Shi

Manish Tandon

Takahiro Kitamura

Masao Itoh

Phuongly Pham

Craig G Bates

John Buell

Jeffrey Yung Wu

Masatoshi Nagamochi

Hidenori Namiki

Masahiro Ota

Zuojun Guo

Jack Walleshauser

Biswajit Das

Tetsunori Fujisawa

Rita Katoch

Saito Higuchi

Aki Yokomizo

Dilip J Upadhyay

Yongil Jin

Hideaki Kageji

Yasuyuki Kaneta

Compounds and methods for EP300 or CBP modulation and indications therefor

The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.

Amino-pyrrolopyrimidinone compounds and methods of use thereof

The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.

Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof

The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof. 

Pyridine compound

A compound represented by the following formula (I) or a salt thereof:   

Amino group-containing pyrrolidinone derivative

A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure. 

Fused substituted aminopyrrolidine derivative

An intermediate for production of a quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria.

Tri-, tetra-substituted-3-aminopyrrolidine derivative

A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided. The compound provided is represented by formula (I): 

A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided. The compound provided is represented by following formula (I): wherein Rand Rrepresent hydrogen atom, or the like; Rrepresents an alkyl group containing 1 to 6 carbon atoms, or the like; Rand Rindependently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like, with the proviso that Rand Rdo not simultaneously represent hydrogen atom; or the substituents Rand Rtogether represent (a) a 3- to 6-membered cyclic structure including the carbon atom shared by Rand Rto form a spirocyclic structure with the pyrrolidine ring; Rand Rindependently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like; Rrepresents a halogen-substituted alkyl group containing 1 to 6 carbon atoms, or the like; Xrepresents hydrogen atom or a halogen atom; A represents nitrogen atom or a moiety represented by formula (II): 

Growing community of inventors

Tokyo, Japan

Hiroaki Inagaki